+91 - 830 - 3146878
The purpose of this study was to measured the efficacy of new herbomineral drug of LAS02 in Liver cancer patients who admitted in Lavanya Ayurvedic Hospital & Research Centre For Cancer and AIDS. The study was conducted after getting ethical clearance. Total 20 patients were enrolled in Lavanaya hospital. These patients were suffering only from Liver cancer not any other diseases. All patients having medication ayuredic herbomineral drug of LAS02 for more than one month treatment. After obtaining prior consent form these patients, venous blood samples was collected from the subjects before and after treatment with herbomineral drug of LAS02 and measured the hematological and biochemical examinations along with Liver cancer in CA(U/ML) and CEA(Ng/ML) tumor biomarker.
A 32.11% and 53.01% percentage level reduction of CA and CEA biomarker in Liver cancer 20 patients as compared to before treated patients (n=20) There was percentage level 10.40% decreased ESR levels in patients after treatment with LAS02 more than one month as compared with before treatment. A 61.55%, 41.14, 15.46%, 27.50% percentage level reduction of hepatic enzymes (SGOT, SGPT, ALP and LDH) in patients after treatment with drug.
The study was conducted after getting ethical clearance from Institutional human ethic committee. Total 20 Liver cancer patients with age (20-80 years) in Lavanya Ayurvedic Hospital and Research Center. These patients were only suffering from Liver Cancer not from any organic diseases. After obtaining prior consent form, venous blood samples was collected from the subjects before (pre) and after treatment (post) with herbomineral drug LAS02 Capsule under aseptic condition. The drug was given to these patients for two months. After collection of blood sample, serum and plasma were separated by centrifugation at 4000 rpm for 10 min. at room temperature for measurement of hematological, biochemical parameters along with in pre and post treated patients.
All hematological and biochemistry parameters Hemoglobin (Hb), lactate dehydragenase (LDH) alkaline phosphate (ALP), Serum glutamate oxaloacetate transminase (SGOT), Serum glutamate pyurvate transminase (SGPT) parameters were measured by fully automatic cell counter and clinical chemistry analyzer.
LDH activity was measured by kit according to protocol provided by supplier (Transasia biomedical). The activity was expressed as an IU/ml.
Levels of serum CA and CEA (CALBIOTECH Diagnostics), was determined using a quantitative sandwich enzyme immunoassay according to manufacturer protocol.
Resulting data were expressed mean ± SD. Percentage parenthesis was observed between pre vs post treated patients with LAS02 drug in Liver cancer.
There were percentage level 53.01% of CEA enzyme activities in patients post treated group in comparison to patient pre treated group. VIEW CHART
There were percentage level 32.11% of CA enzyme activities in patients post treated group in comparison to patient pre treated group. VIEW CHART
The percentage lavel of ESR was also found to be 10.40% decreased in the patients after treatment with LAS02 in comparison to pre treatment.
There were slightly increased Hb(%), hematocrit and RBC levels in patient treated group as compared with patient pre treated group. VIEW CHART
There were percentage lavel of LDH and ALP enzyme was found to be 27.50% and 15.46% in patients post treated group in comparison to patient pre treated group. VIEW CHART
On the basis of these findings it is suggested that the herbomineral drug LAS02 is most effective medicine for prevention of Liver cancer.
The purpose of this study was to evaluate the acute oral toxicity study of LAS02 in female Sprague Dawley rat model. [...]
The purpose of this study was to evaluate the maximum tolerated dose of LAS02 in Sprague dawley female rat. [...]
The aim of this study was to evaluate the maximum tolerated dose of LAS02 in female Sprague Dawley rat. [...]